SCHEMBL6542845

SCHEMBL6542845

CCOc1cc(C=NO)ccc1-c1cc2c(cc1C)C(C)(C)CCC2(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
RXRA P19793 4/20 0.42
PKM P14618 2/20 0.42
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HNF4A P41235 2/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RXRB P28702 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542841 1.00 GAA (0.46) GAAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL6542800 0.91 GAA (0.46) GAAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL6542802 0.91 GAA (0.46) GAAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL6541444 0.85 ALDH1A1 (0.47) ALDH1A1RXRAHNF4AMAPTHPGD
SCHEMBL6542665 0.84 RXRA (0.49) ALDH1A1MEN1KMT2ARXRARXRB
SCHEMBL6542662 0.84 RXRA (0.49) ALDH1A1MEN1KMT2ARXRARXRB
SCHEMBL6541749 0.82 RXRA (0.53) MEN1KMT2ARXRARXRBRXRG
SCHEMBL6541488 0.81 RXRA (0.52) ALDH1A1MEN1KMT2ARXRARXRB
SCHEMBL6541492 0.81 RXRA (0.52) ALDH1A1MEN1KMT2ARXRARXRB
SCHEMBL6541649 0.80 RXRA (0.46) ALDH1A1MEN1KMT2ACYP1A2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421061-A4 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA INCYTE SAN DIEGO INC (US) 2004-12-22 EP disclosed
EP-1421061-A1 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA Incyte San Diego Incorporated (US) 2004-05-26 EP disclosed
US-20030083357-A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia ORTHO MCNEIL PHARMACEUTICAL INC. 2003-05-01 US disclosed
WO-2003016267-A1 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA INCYTE SAN DIEGO INCORPORATED (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083357-A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia OAT, CPT1A, CYP27A1 GAA 637/4885ALDH1A1 643/4885MEN1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.